The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

General Updates | Looking forward to EHA: the most exciting updates in MPNs

Name: Looking forward to EHA: the most exciting updates in MPNs
Uploaded: 2022-05-16T00:00:00Z
Duration: 51 s
Description: John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, shares the most awaited updates in myeloproliferative neoplasms (MPNs) that will be presented at this year’s EHA congress, including the MOMENTUM data (NCT04173494), and data on the combination of ruxolitinib with navitoclax and pelabresib. This interview took place virtually.

John Mascarenhas • 16 May 2022

General Updates

Myeloproliferative Neoplasms Momelotinib Pelabresib Ruxolitinib

MOMENTUM

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, shares the most awaited updates in myeloproliferative neoplasms (MPNs) that will be presented at this year’s EHA congress, including the MOMENTUM data (NCT04173494), and data on the combination of ruxolitinib with navitoclax and pelabresib. This interview took place virtually.

Disclosures

Research funding paid to Prof. Mascarenhas’ institution from Incyte, Novartis, Celgene, BMS, CTI Bio, Merck, Roche, Kartos, PharmaEssentia, Abbvie, and Geron. Consulting fees from Novartis, Incyte, CTI Bio, Constellation, Abbvie, Roche, Kartos, PharmaEssentia, Sierra Onc, Galecto, GSK, Karyopharm, Celgene, Geron and BMS.